Navigation Links
Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
Date:9/15/2008

SAN MARINO, Calif., Sept. 15 /PRNewswire/ -- Epeius Biotechnologies Corporation today announced that Rexin-G, its lead product in development for metastatic cancer, has been highlighted in a recent NEWS article published by the Journal of the National Cancer Institute (JNCI, Sept. 9, 2008). The article, authored by Vickie Brower, describes recent advances and new approaches in genetic medicine that may succeed where small molecules and proteins have failed. Noted for its recent demonstrations of safety and single-agent efficacy in several types of metastatic cancers that were refractory to standard chemotherapy, Rexin-G is described as the world's second commercially approved gene therapy-while it remains the first and so far only targeted, injectable genetic medicine that has been effectively validated in the clinic.

Rexin-G, with its elegant tumor-targeting biotechnologies, performs a vital surveillance function for the benefit of the cancer patient: distributing throughout the general circulation, while constantly seeking-out and accumulating in primary tumors and metastatic tissues that have spread throughout the body. Within minutes, the tumor-targeted nanoparticles of Rexin-G begin to accumulate within the cancerous lesions to high levels, delivering a lethal payload of genetic medicine selectively to cancer cells and their attendant blood supply, while sparing normal cells and tissues. In a series of four clinical trials that are currently ongoing in the United States, Rexin-G has demonstrated dose-dependent improvements in tumor-control indices, while exhibiting no dose-limiting toxicities. The JNCI article noted that Rexin-G has been granted Orphan Drug Status by the U.S. FDA for three different types of cancers: osteosarcoma, soft-tissue sarcoma, and pancreatic cancer. Ten months ago, Rexin-G was formally approved in the Philippines for the treatment of all solid tumors that are refractory to standard chemotherapies.

The JNCI NEWS article also highlighted the second tumor-targeted agent in development by Epeius Biotechnologies, describing Reximmune-C as an immune stimulant, or personalized cancer vaccine, designed to be used alone or in combination with Rexin-G. Reximmune-C incorporates a powerful cytokine gene, in place of the cytocidal gene used in Rexin-G, to deliver an immune- stimulating pulse to activate a patient's own immune cells in the area of residual tumors to prevent recurrence. Remarkably, several of the prominent cancer researchers, companies, and academicians interviewed for the JNCI article focused-in principle-on the very same issues that Epeius Biotechnologies, with its definitive molecular engineering platform, has actually managed to address. The JNCI article is well worth reading.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about our pipeline of proprietary biotechnologies that are currently available for licensing and clinical development, please visit our website, http://www.epeiusbiotech.com.

For more information about Rexin-G, Reximmune-C, and on-going clinical trials in the USA and abroad, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.

*(Logo Link: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Epeius Biotechnologies Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
2. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
3. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
4. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
5. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
6. MacroGenics Acquires Raven Biotechnologies
7. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
8. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
9. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing
10. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
11. Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer ... that they have entered into a multiyear collaboration to identify and characterize novel ... additional tools for gene editing across all applications. , Under the terms of ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO ... ASTER Labs ), Inc. has been selected for membership in ARCS Alumni ...
(Date:10/11/2017)... INDIANAPOLIS , Oct. 11, 2017  VMS BioMarketing, a ... of a nationwide oncology Clinical Nurse Educator (CNE) network, which ... growing need for communication among health care professionals to enhance ... physicians, nurses, office staff, and other health care professionals to ... for breast cancer. ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and ... rebranding initiative announced today. The bold new look is part of a transformation ... moves into a significant growth period. , It will also expand its service offering ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
Breaking Biology News(10 mins):